ArticleAnnals of dermatology2025

Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial.

Subin Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.